This company listing is no longer active
Poseida Therapeutics (2RZ) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
2RZ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Poseida Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.05 |
| 52 Week High | US$9.36 |
| 52 Week Low | US$1.81 |
| Beta | 1.63 |
| 1 Month Change | 3.96% |
| 3 Month Change | 282.83% |
| 1 Year Change | 209.93% |
| 3 Year Change | 63.06% |
| 5 Year Change | n/a |
| Change since IPO | -21.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2RZ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.8% | 0.8% | -2.2% |
| 1Y | 209.9% | -2.4% | 3.4% |
Return vs Industry: 2RZ exceeded the German Biotechs industry which returned -9.8% over the past year.
Return vs Market: 2RZ exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| 2RZ volatility | |
|---|---|
| 2RZ Average Weekly Movement | 74.2% |
| Biotechs Industry Average Movement | 5.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2RZ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2RZ's weekly volatility has increased from 37% to 74% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 350 | Kristin Yarema | poseida.com |
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC.
Poseida Therapeutics, Inc. Fundamentals Summary
| 2RZ fundamental statistics | |
|---|---|
| Market cap | €903.31m |
| Earnings (TTM) | -€58.72m |
| Revenue (TTM) | €145.79m |
Is 2RZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2RZ income statement (TTM) | |
|---|---|
| Revenue | US$150.86m |
| Cost of Revenue | US$172.43m |
| Gross Profit | -US$21.57m |
| Other Expenses | US$39.19m |
| Earnings | -US$60.76m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.62 |
| Gross Margin | -14.30% |
| Net Profit Margin | -40.28% |
| Debt/Equity Ratio | 67.5% |
How did 2RZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 10:42 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Poseida Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| null null | H.C. Wainwright & Co. |
| Yu He | H.C. Wainwright & Co. |